Reducing Risk of Transplantation for People with IgA Nephropathy: What Managed Care Pharmacists Can Do to Help Optimize Treatment
This activity is jointly provided by the Academy of Managed Care Pharmacy, Global Education Group, and PlatformQ Health Education, LLC, in collaboration with Kidney Disease: Improving Global Outcomes (KDIGO).
Because it is “silent” or asymptomatic, patients with immunoglobulin-A nephropathy (IgAN) often experience diagnostic delay. A common cause of kidney failure that can necessitate kidney transplantation, IgAN can also recur after transplantation, leading to allograft failure. People with IgAN suffer from heightened pain and fatigue, as well as negative impacts on quality of life (QoL) and mental health.
Several targeted treatment options with improved efficacy and safety compared to current care have recently been or are being developed. These therapies are poised to address unmet needs and reduce risk of transplantation.
Join an expert nephrologist and pharmacist to discuss these new and emerging treatment options, up-to-date evidence on their safety and efficacy, and recommendations from practice guidelines. Managed care pharmacists will be prepared to enhance access to these beneficial treatments and include them in medication-management programs for appropriate patients with IgAN.
Follow the link below!